To further promote academic exchange in the field of infectious diseases and liver diseases, enhance the diagnosis and treatment capabilities for infection-related liver injury and drug-induced liver disease (DILI), and share the latest research findings and clinical practice guidelines, the "Academic Conference on Infections and Drug-Induced Liver Diseases," jointly organized by the Chongqing Medical Association and the Chengdu High-Tech Zone Medical Association, is scheduled to take place from November to December 2025. The conference will adopt a hybrid model, combining both online and offline participation. This event will focus on the latest advancements, share practical experiences, and warmly invite colleagues to actively participate in exploring new technologies and directions in the field of liver diseases, thereby advancing the discipline to new heights.

With the emergence of novel pathogens, the increasingly widespread use of drugs, and the growing prevalence of patient comorbidities, the etiological identification and treatment decision-making for liver injury have become increasingly complex. This conference aims to establish a collaborative platform that integrates cutting-edge research, clinical practice, and multidisciplinary perspectives. It will delve into the translational pathways from molecular mechanisms to bedside applications, analyze the intrinsic patterns of synergy between various infectious factors and drug toxicity, share experiences and reflections in the diagnosis and treatment of complex cases, foster consensus on early warning, precise diagnosis, and personalized management of related liver diseases, and promote the optimization and implementation of diagnostic and treatment protocols. Ultimately, the goal is to achieve joint advancements in theoretical understanding and clinical efficacy, allowing more patients to benefit from interdisciplinary collaboration and innovation.